Oncotelic Therapeutics and TechForce Robotics signed a Joint Development, Manufacturing, and Licensing Agreement on March 31, 2026. The partnership aims to integrate Oncotelic's proprietary PDAOAI platform with TechForce's robotic hardware to create GMP-compliant systems for pharmaceutical environments. Oncotelic retains exclusive ownership of all AI-related foreground intellectual property and data generated by the product. The agreement includes a 12-month exclusivity period post-termination, preventing TechForce from licensing jointly developed IP to third-party pharmaceutical competitors. Commercial terms, including revenue sharing and royalty rates, are deferred to a future Commercialization and Licensing Agreement.